<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180100</url>
  </required_header>
  <id_info>
    <org_study_id>PKUSH-GNY-2013-01</org_study_id>
    <nct_id>NCT02180100</nct_id>
  </id_info>
  <brief_title>Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis</brief_title>
  <official_title>A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Shyndec Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Shenzhen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study were to demonstrate comparable safety and efficacy of
      Terconazole Vaginal Suppositories, 80 mg and fluconazole in the treatment of subjects with
      severe vulvovaginal candidiasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study were to demonstrate comparable safety and efficacy of Terconazole Vaginal
      Suppository 80 mg inserted intravaginally once daily before bedtime for 6 consecutive days
      and oral fluconazole 150mg at day 1 and day 4 in the treatment of subjects with severe
      vulvovaginal candidiasis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects in Each Treatment Group With Therapeutic Cure</measure>
    <time_frame>Visit 3: Day 35-42</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Terconazole Vaginal Suppository</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terconazole Vaginal Suppository</intervention_name>
    <description>Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days</description>
    <arm_group_label>Terconazole Vaginal Suppository</arm_group_label>
    <other_name>Tekangzuo Yindao Shuan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a
             numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3)
             with a minimum VVC Composite Signs/Symptoms score of 7

          -  Subject completes the informed consent process

          -  Subject agrees to take study medication when scheduled

          -  Subject complies with all clinical trial instructions. Commits to all follow-up visits

          -  Subject agrees to abstain from sexual intercourse from the time of randomization
             through the first seven days immediately following treatment

        Exclusion Criteria:

          -  had any other sexually transmitted disease or gynaecological abnormality requiring
             treatment

          -  had a disease known to predispose to candidiasis such as diabetes mellitus, or were
             receiving antibiotics or corticosteriods

          -  had used antifungal medication in the week before entry; or

          -  were expected to menstruate within seven days of the start of treatment

          -  infected more than one candida species
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shangrong Fan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Shenzhen Hosptal</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://mmy.oxfordjournals.org/content/early/2015/04/14/mmy.myv017.long</url>
    <description>Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25877666</url>
    <description>Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis</description>
  </link>
  <results_reference>
    <citation>Li T, Zhu Y, Fan S, Liu X, Xu H, Liang Y. A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. Med Mycol. 2015 Jun;53(5):455-61. doi: 10.1093/mmy/myv017. Epub 2015 Apr 15.</citation>
    <PMID>25877666</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Shenzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shangrong Fan</investigator_full_name>
    <investigator_title>Prof of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Terconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

